Evidence map›Paper›PMID 41125659›Full record

ArticleScientific reports2025

Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomallei.

Jason E Cummings, Danara Flores, Vincent E Guglielmi, Gregory Dooley, M R K Alley, Richard A Slayden

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jason E CummingsMicrobiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, 80523-0922, USA.
Danara FloresMicrobiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, 80523-0922, USA.
Vincent E GuglielmiMicrobiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, 80523-0922, USA.
Gregory DooleyEnvironmental Health and Radiological Sciences, Colorado State University, Fort Collins, CO, 80523-0922, USA.
M R K AlleyAN2 Therapeutics, Menlo Park, CA, 94027, USA.
Richard A SlaydenMicrobiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, 80523-0922, USA. richard.slayden@colostate.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melioidosis, caused by Burkholderia pseudomallei, remains a major therapeutic challenge due to high relapse rates and intrinsic antibiotic resistance. Epetraborole (EBO), a leucyl-tRNA synthetase inhibitor, represents a novel therapeutic approach with a distinct mechanism of action compared to standard-of-care antibiotics. Preclinical studies included minimum inhibitory concentration (MIC) determination, pharmacokinetic (PK) profiling, dose range and fractionation studies, and efficacy assessments in a 24-hour post-bacterial challenge model of a murine B. pseudomallei lung infection. EBO demonstrated a clear dose-dependent reduction in lung bacterial burden. Doses ≥ 200 mg/kg (achieving area under the curve (AUC)

Indexed as

Anti-Bacterial AgentsBoron CompoundsBurkholderia pseudomalleiMelioidosisAnimalsDisease Models, AnimalFemaleHumansLeucine-tRNA LigaseMaleMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsBoron CompoundsLeucine-tRNA Ligase

Identifiers

PMID41125659
PMCPMC12546574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.